Oral cryotherapy reduces mucositis and opioid use after myeloablative therapy

a randomized control trial

Document identifier: oai:dalea.du.se:2581
Access full text here:10.1007/s00520-007-0245-8
Keyword: Medical and Health Sciences, Health Sciences, Medicin och hälsovetenskap, Hälsovetenskaper, Oral cryotherapy, Bone marrow transplantation, Mucositis, Oral pain, Opioid use, Oral cryoterapi för patienter som behandlas med cytostatika
Publication year: 2007
Relevant Sustainable Development Goals (SDGs):
SDG 3 Good health and wellbeing
The SDG label(s) above have been assigned by OSDG.ai


Introduction. Mucositis is a major complication in myeloablative therapy, which often necessitates advanced pharmacological pain treatment, including i.v. opioids. Attempts to prevent oral mucositis have included oral cryotherapy, which has been shown to reduce mucositis, but there is a lack of knowledge concerning the effect of oral cryotherapy on opioid use by reducing the mucositis for patients treated with myeloablative therapy before bone marrow transplantation (BMT). 

Aim. The aim of the present study was to evaluate if oral cryotherapy could delay or alleviate the development of mucositis and thereby reduce the number of days with i.v. opioids among patients who receive myeloablative therapy before BMT. 

Materials and methods. Eighty patients 18 years and older, scheduled for BMT, were included consecutively and randomised to oral cryotherapy or standard oral care. A stratified randomisation was used with regard to type of transplantation. Intensity of pain, severity of mucositis and use of opioids were recorded using pain visual analogue scale (VAS) scores, mucositis index scores and medical and nursing charts. 

Results. This study showed that patients receiving oral cryotherapy had less pronounced mucositis and significantly fewer days with i.v. opioids than the control group. In the autologous setting, cryotherapy patients also needed significantly lower total dose of opioids. 

Conclusion. Oral cryotherapy is an effective and well-tolerated therapy to alleviate mucositis and consequently reduce the number of days with i.v. opioids among patients treated with myeloablative therapy before BMT.


Anncarin Svanberg

Department of Haematology, Akademiska Hospital, Uppsala
Other publications >>

Gunnar Birgegård

Other publications >>

Kerstin Öhrn

Högskolan Dalarna; Vårdvetenskap med inriktning mot munhälsa
Other publications >>

Record metadata

Click to view metadata